Country: Kanada
Bahasa: Inggeris
Sumber: Health Canada
PEMBROLIZUMAB
MERCK CANADA INC
L01FF02
PEMBROLIZUMAB
25MG
SOLUTION
PEMBROLIZUMAB 25MG
INTRAVENOUS
4ML
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0156910003; AHFS:
APPROVED
2016-08-09
_KEYTRUDA® (pembrolizumab) _ _Page 1 of 282_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION KEYTRUDA® pembrolizumab solution for infusion 100 mg/4 mL vial Antineoplastic agent, monoclonal antibody Keytruda, indicated for: • Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT. • Adult and pediatric patients with refractory Primary Mediastinal B-cell Lymphoma (PMBCL) or who have relapsed after 2 or more lines of therapy, as monotherapy. • Adult patients with locally advanced unresectable or metastatic urothelial carcinoma, as monotherapy, who are not eligible for any platinum-containing chemotherapy. • Adult patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ (CIS) with or without papillary tumours who are ineligible for or have elected not to undergo cystectomy. has been issued market authorization WITH CONDITIONS, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information for Keytruda please refer to Health Canada’s Notice of Compliance with conditions - drug products web site: https://www.canada.ca/en/health-canada/services/drugs-health- products/drug-products/notice-compliance/conditions.html. Keytruda, indicated for the: • Treatment of adult patients with unresectable or metastatic melanoma who have not received prior treatment with ipilimumab. Subjects with BRAF V600 mutant melanoma may have received prior BRAF inhibitor therapy. • Treatment of adult patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor. • Adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB or IIC melanoma follo Baca dokumen lengkap